Publishing statistically significant results with questionable clinical importance: Focus on antidepressant use in pregnancy

Journal of Clinical Psychiatry

Volumn 73, Issue 11, 2012, Pages 1443-1446

  Einarson, Adrienne ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

BIRTH DEFECT; CONGENITAL MALFORMATION; DEPRESSION; DRUG INDUSTRY; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HEART DISEASE; HUMAN; MENTAL HEALTH; NOTE; PERSISTENT PULMONARY HYPERTENSION; PREGNANCY; PRIORITY JOURNAL; RISK ASSESSMENT; TERATOGENICITY;

EID: 84869238653     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12com08192     Document Type: Note

References (16)

1. Grigoriadis S, Robinson GE. Gender issues in depression. Ann Clin Psychiatry. 2007;19(4):247-255. doi:10.1080/10401230701653294 PubMed (Pubitemid 350208795)
2. Marcus SM. Depression during pregnancy: rates, risks and consequences: Motherisk Update 2008. Can J Clin Pharmacol. 2009;16(1):e15-e22. PubMed
3. Alwan S, Reefhuis J, Rasmussen SA, et al National Birth Defects Prevention Study. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol. 2011;51(2):264-270. doi:10.17/09127010373928 PubMed
4. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf. 2005;14(12):823-827. doi:10.102/pds.1084 PubMed (Pubitemid 43056107)
5. Clinical Study Register. Epidemiology study EPIP083: preliminary report on bupropion in pregnancy and the occurrence of cardiovascular and major congenital malformation; 2007. GlaxoSmithKline Web site. www.gsk- clinicalstudyregister.com/ Accessed October 1, 2012.
6. FDA News Release. FDA advising of risk of birth defects with Paxil. Agency requiring updated product labeling. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2005/ucm108527.htm. US Food and Drug Administration Web site. Accessed October 1, 2012.
7. Selective serotonin reuptake inhibitor (SSRI) antidepressants: drug safety communication-use during pregnancy and potential risk of persistent pulmonary hypertension of the newborn. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm283696.htm. US Food and Drug Administration Web site. Accessed October 8, 2012.
8. Scialli AR. Paroxetine exposure during pregnancy cardiac malformations. Birth Defects Res A Clin Mol Teratol. 2010;88(3):175-177. PubMed
9. Bérard A. Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence? Birth Defects Res A Clin Mol Teratol. 2010;88(3):171-174. PubMed
10. Paxil lawsuit. www.schmidtandclark.com/paxil. Accessed October 1, 2012.
11. Paxil birth defects.www.lawyersandsettlements.com/case/paxil-heart- defects-newborn.html. Accessed October 1, 2012.
12. Diav-Citrin O, Ornoy A. Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat [published online ahead of print December 10, 2011]? Obstet Gynecol Int. PubMed
13. Einarson TR, Lee C, Smith R, et al. Quality and content of abstracts in papers reporting about drug exposures during pregnancy. Birth Defects Res A Clin Mol Teratol. 2006;76(8):621-628. doi:10.102/bdra.20289 PubMed (Pubitemid 44465324)
14. Mulder E, Davis A, Gawley L, et al. Negative impact of non-evidence-based information received by women taking antidepressants during pregnancy from health care providers and others. J Obstet Gynaecol Can. 2012;34(1):66-71. PubMed
15. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci. 2001;26(1):44-48. PubMed (Pubitemid 32185179)
16. Spier R. The history of the peer-review process. Trends Biotechnol. 2002;20(8):357-358. doi:10.1016/S0167-79(02)01985-6 PubMed